Cabaletta Bio Overview
Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide a deep and durable, perhaps curative, treatment for patients with autoimmune diseases. The CABA™ platform, in combination with Cabaletta Bio's proprietary technology, has advanced a growing pipeline that currently includes potential treatments for patients with:
- Mucosal pemphigus vulgaris
- MuSK-associated myasthenia gravis
- PLA2R-associated membranous nephropathy
- Mucocutaneous pemphigus vulgaris
- Hemophilia A with FVIII alloantibodies
Cabaletta Bio's headquarters are located in Philadelphia, PA. For more information, visit www.cabalettabio.com.